Mark Fallen, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Boston Scientific at 27.6% of the total. Reporting peaked in 2022 at $1,276 and has fallen 84.0% since, to $203 in 2025.
Across 108 payments — averaging $43.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Axonics, Inc.$493
- Coloplast$332
- SRS Medical Systems, Inc.$293
- Olympus America Inc.$280
- Teleflex LLC$279
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,52997%
- Education$1443%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 12 | $1,290 |
| Axonics, Inc. | 10 | $493 |
| Coloplast | 17 | $332 |
| SRS Medical Systems, Inc. | 2 | $293 |
| Olympus America Inc. | 3 | $280 |
| Teleflex LLC | 2 | $279 |
| Dendreon Pharmaceuticals LLC | 10 | $218 |
| Neotract Inc. | 3 | $218 |
| Johnson & Johnson(3 entities) | 4 | $169 |
| Antares Pharma, Inc. | 11 | $151 |
| Conmed Corporation | 1 | $138 |
| Agiliti Surgical, Inc. | 1 | $130 |
| AbbVie(2 entities) | 5 | $77 |
| Convatec Inc. | 3 | $70 |
| Telix Pharmaceuticals | 1 | $48 |
| Dornier Medtech America, Inc | 1 | $46 |
| Myovant Sciences Inc. | 2 | $39 |
| Progenics Pharmaceuticals, Inc. | 2 | $38 |
| Halozyme Inc | 2 | $37 |
| AstraZeneca | 1 | $35 |
| Accord Healthcare, Inc. | 1 | $34 |
| Procept Biorobotics Corporation | 1 | $31 |
| Bluewind Medical | 1 | $28 |
| Bayer | 2 | $26 |
| 180 Medical, Inc. | 1 | $23 |
| ABC Home Medical Supply, Inc. | 1 | $22 |
| Ambu Inc. | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $18 |
| Urogen Pharma, Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Tolmar, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LithoVue$585
- UroLift$424
- UroCuff$293
- iTIND System$263
- Axonics r-SNM System$166
- Tria Firm$156
- GENERAL KIDNEY STONE DISEASE$150
- Axonics$140
- AIRSEAL$138
- Sonablate$130
- MONARCH$118
- SPACEOAR VUE$106
How this compares
$4,674 in reported general payments places this provider in the 80th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 27 | $391,955 |
| GemtesaVibegron | 112 | $84,027 |
| Abiraterone Acetate | 48 | $61,450 |
| MyrbetriqMirabegron | 88 | $61,424 |
| OrgovyxRelugolix | 12 | $29,574 |
| Finasteride | 665 | $10,447 |
| Testosterone | 19 | $6,322 |
| Tamsulosin Hcl | 312 | $5,634 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 12 | $3,023 |
| Testosterone Cypionate | 20 | $1,254 |
| Oxybutynin Chloride ErOxybutynin Chloride | 70 | $783 |
| Dutasteride | 22 | $584 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $561 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 83 | $448 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 11 | $316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $169 | $391,95527 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $61,42488 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 247 urology providers in Minnesota.
Other urology in Edina
- Steven BernsteinEdina$271K
- Joseph MahonEdina$86K
- Stephen OverholserEdina$20K
- Jason KemberlingEdina$19K
- Dean TortorelisEdina$19K
- Roland UgarteEdina$9K
- Paul FaddenEdina$6K
- Jeffry TwidwellEdina$6K
- Rachel MannEdina$6K
- Chase SovellEdina$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.